EUVIMED · CrossrefZeitschrift
The Lancet Oncology
ISSN 1470-2045 · Elsevier BV
Neueste Artikel
Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial
Global health expenditures on cancer control: a cross-sectional analysis
Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial
Survival in patients with renal cell carcinoma and brain metastases: an update of the Renal Graded Prognostic Assessment
Estimated global treatment costs for 31 cancer types by stage, year, and follow-up period: a systematic review and modelling study
Cancer in the Commonwealth: a Lancet Oncology Commission
Genomically matched targeted therapy for ovarian clear cell carcinoma
Armamentarium of scientific tools enough to win cancer fight in the Commonwealth
Small island developing states and the Commonwealth
From Commonwealth ambition to African action on cancer
Addressing gaps in cancer care in the Caribbean
Co-targeting angiogenesis and immune checkpoints in breast cancer
The Commonwealth's cancer moment
Turning shared inheritance into shared action
Mastering the role of radiotherapy in pancreatic ductal adenocarcinoma: who and why?
A council of the willing for cancer in the Commonwealth
Kenya's new cancer treatment targets test health system capacity
Türkiye Health Minister calls for stricter tobacco control measures
Latin America round-up: cancer care under pressure
Review recommends radical overhaul to multidisciplinary working in NHS cancer services
Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial
Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis
Brazil improves access to cancer screening and care
WHO releases framework for expanding access to early breast cancer care
India caps price of 137 cancer drugs
2026 ESMO Congress
Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial
EUVIMED